Sogen Data · Datasets · 数据专题

前列腺癌复发轴数据集锦

单细胞 · bulk 转录组

本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。

人源单细胞

Human · Single-cell

  1. 01 GSE271675 对五名接受根治性前列腺切除术和盆腔淋巴结清扫术的前列腺癌患者,分别采集其前列腺原发灶及区域淋巴结转移灶的肿瘤细胞,采用单细胞多组学测序技术同时检测基因表达与染色质可及性,比较不同部位肿瘤细胞的表型异质性及克隆架构特征。 人源 · 44 例 · GPL24676 · 2025/12/01

    设计对五名接受根治性前列腺切除术和盆腔淋巴结清扫术的前列腺癌患者,分别采集其前列腺原发灶及区域淋巴结转移灶的肿瘤细胞,采用单细胞多组学测序技术同时检测基因表达与染色质可及性,比较不同部位肿瘤细胞的表型异质性及克隆架构特征。

    摘要Identifying drivers of cancer progression to guide treatment selection is hindered by limited abilities to understand tumor heterogeneity’s impact on evolution. Here, we delineated the phenotypic variability across ~300,000 prostate tumor cells collected from multi-loci in primary and matched locoregional metastases. We found inter-patient heterogeneity to be confined to malignant populations. While malignant populations exhibit intra-locus heterogeneity, they maintain inter-loci phenotypic similarity within a patient’s prostate gland. Furthermore, the inter-loci malignant population similarity is paired with a shared clonal architecture. Lastly, we show that malignant populations disseminating to locoregional lymph nodes mirror the clonal architecture and phenotypic heterogeneity observed across primary tumor loci while showcasing cell state transition to inflammatory phenotypes. These findings provide insights into four distinct measures of tumor heterogeneity, revealing diverse evolutionary paths across patients converging to common phenotypic adaptations in early prostate cancer progression.

  2. 02 GSE306625 整合四个新鲜人类前列腺癌样本的单细胞 RNA 测序数据,包含三例转移性去势抵抗性前列腺癌 (mCRPC) 和一例激素敏感性前列腺癌 (HSPC),通过单细胞悬液富集与转录组分析识别神经内分泌样亚型,比较不同亚型的转录特征并验证 STMN1 作为预后标志物的临床相关性。 人源 · 4 例 · GPL24676 · 2026/06/02

    设计整合四个新鲜人类前列腺癌样本的单细胞 RNA 测序数据,包含三例转移性去势抵抗性前列腺癌 (mCRPC) 和一例激素敏感性前列腺癌 (HSPC),通过单细胞悬液富集与转录组分析识别神经内分泌样亚型,比较不同亚型的转录特征并验证 STMN1 作为预后标志物的临床相关性。

    摘要Second-generation hormonal therapy inhibits castration-resistant prostate cancer (CRPC), but the tumor eventually recurs as neuroendocrine prostate cancer (NEPC) and turns lethal. With limited treatment options for advanced CRPC exhibiting an NEPC phenotype, we aimed to elucidate the mechanisms of adeno-to-neuroendocrine lineage transition to guide the development of effective therapeutic strategies. By integrating single-cell RNA sequencing data from fresh human CRPC cases, we identified three distinct neuroendocrine subtypes in CRPC: a REST-dependent subtype (NE I), an N-Myc-dependent subtype (NE II), and a combined N-Myc/REST subtype (NE I+II) among 5,797 neuroendocrine-like epithelial cells. These subtypes were validated through multiplex immunofluorescence staining. Single-cell trajectory analysis uncovered N-Myc and REST as key transcription factors driving these distinct neuroendocrine lineages, and multi-omics time course analysis of publicly available transcriptomic data further recapitulated the N-Myc and REST lineage progression. Notably, we observed PSMA loss in the N-Myc lineage and identified STMN1 as a biomarker for PSMA-negative NEPC. We further validated the prognostic value of STMN1 in the TCGA dataset and in 60 in-house CRPC tissues. Our analyses provide valuable insights into the adeno-to-neuroendocrine lineage transition in prostate cancer, offering a powerful tool for early detection of lethal NEPC phenotypes and guiding 177Lu-PSMA-617 therapy for advanced CRPC.

人源bulk 转录组

Human · Bulk RNA-seq

  1. 01 GSE10645 对前列腺癌复发的男性患者,采用病例对照设计,分别采集系统性进展病例组、PSA复发对照组和无疾病进展对照组的前列腺组织进行基因表达检测,比较各组间基因表达差异。系统性进展病例组为在PSA复发后5年内出现系统性疾病(如骨扫描或CT扫描阳性)的患者,PSA复发对照组为无系统性进展且与病例组在出生年份、PSA复发年份和初始病理Gleason评分匹配的患者,无疾病进展对照组为在前列腺切除术后7年内无PSA升高且与病例组匹配的患者。 人源 · 1192 例 · GPL5873;5858 · 2008/06/10

    设计对前列腺癌复发的男性患者,采用病例对照设计,分别采集系统性进展病例组、PSA复发对照组和无疾病进展对照组的前列腺组织进行基因表达检测,比较各组间基因表达差异。系统性进展病例组为在PSA复发后5年内出现系统性疾病(如骨扫描或CT扫描阳性)的患者,PSA复发对照组为无系统性进展且与病例组在出生年份、PSA复发年份和初始病理Gleason评分匹配的患者,无疾病进展对照组为在前列腺切除术后7年内无PSA升高且与病例组匹配的患者。

    摘要After therapy for prostate cancer many men develop a rising PSA. Such men may develop a local or metastatic recurrence that warrants further therapy. However many men will have no evidence of disease progression other than the rising PSA and will have a good outcome. A case-control design, incorporating test and validation cohorts, was used to test the association of gene expression results with outcome after PSA recurrence. Since clinical training and validation analysis requires tissue from patients with sufficient follow-up time, for this study we sampled individuals from the Mayo Radical Retropubic Prostatectomy (RRP) Registry. The registry consists of a population of men who received prostatectomy as their first treatment for prostate cancer at the Mayo Clinic (For a current description and use of the registry; see PMID: 17418069). As systemic progression is relatively infrequent, we designed a case-control study nested within a cohort of men with a rising PSA. Between 1987-2001, inclusive, 9,989 previously-untreated men had RRP at Mayo. On follow-up, 2,131 developed a rising PSA (>30 days after RRP) in the absence of concurrent clinical recurrence. PSA rise was defined as a follow-up PSA >= 0.20 ng/ml, with the next PSA at least 0.05 ng/ml higher or the initiation of treatment for PSA recurrence (for patients whose follow-up PSA was high enough to warrant treatment). This group of 2,131 men comprises the underlying cohort from which SYS cases and PSA controls were selected. Within 5 years of PSA rise, 213 men developed systemic progression (SYS cases), defined as a positive bone scan or CT scan. Of these, 100 men succumbed to a prostate cancer-specific death, 37 died from other causes and 76 remain at risk. PSA recurrence controls (213) were selected from those men without systemic progression within 5 years after the PSA rise and were matched (1:1) on birth year, calendar year of PSA rise and initial diagnostic pathologic Gleason score (<=6, 7+). Twenty of these men developed systemic progression greater than 5 years after initial PSA rise and 9 succumbed to a prostate cancer-specific death. A set of 213 No Evidence of Disease (NED) Progression controls were also selected from the Mayo RRP Registry of 9,989 men and used for some comparisons. These controls had RRP from 1987-1998 with no evidence of PSA rise within 7 years of RRP. The median (25th, 75th percentile) follow-up from RRP was 11.3 (9.3, 13.8) years. The NED controls were matched to the systemic progression cases on birth-year, calendar year of RRP and initial diagnostic Gleason Score. Computerized optimal matching was performed to minimize the total distance between cases and controls in terms of the sum of the absolute difference in the matching factors (PMID: 8728456). All paraffin-embedded blocks from eligible men were identified and each block was surveyed for the tissue present (primary and secondary Gleason cancer regions, normal and metastatic lymph nodes, etc.). Of the 639 eligible patients, paraffin blocks were available on 623 (97.5%). Similarly, RNA was successfully isolated and the DASL assays successfully performed on a very high proportion of patients/specimens: Usable RNA was prepared from all 623 blocks, and the Cancer Panel and custom prostate cancer panel DASL arrays were both successful on 596 RNA specimens (95.7% of RNAs; 93.3% of design patients). Keywords: outcome prediction

  2. 02 GSE70770 对前列腺癌复发患者进行分子特征分析,采集其良性及肿瘤组织样本,采用RNA测序和SNP芯片技术,比较肿瘤组织与良性组织的基因表达和基因组变异特征。 人源 · 808 例 · GPL10558;16104;20641;6801 · 2015/07/30

    设计对前列腺癌复发患者进行分子特征分析,采集其良性及肿瘤组织样本,采用RNA测序和SNP芯片技术,比较肿瘤组织与良性组织的基因表达和基因组变异特征。

    摘要This SuperSeries is composed of the SubSeries listed below.

  3. 03 GSE201284 对前列腺癌复发患者和缓解患者进行整合分析,采集其血液样本和前列腺组织样本进行RNA测序,比较两组间前列腺组织的转录组差异。 人源 · 370 例 · GPL24676 · 2022/04/27

    设计对前列腺癌复发患者和缓解患者进行整合分析,采集其血液样本和前列腺组织样本进行RNA测序,比较两组间前列腺组织的转录组差异。

    摘要Prostate cancer is readily curable if detected early. The overall goal of this study is to conduct integrative profiling of tumor and blood genomics and transcriptomics.

  4. 04 GSE116918 对接受根治性放射治疗(联合雄激素剥夺治疗)的 248 例局部/局部晚期前列腺癌患者进行基因表达分析,采集前列腺癌组织样本,采用聚类分析评估 Metastatic Assay 在预测生化复发无病生存期(BFFS)和无转移生存期(MFS)中的预后价值,比较 Metastatic Assay 阳性与阴性患者的生存差异。 人源 · 248 例 · GPL25318 · 2018/07/12

    设计对接受根治性放射治疗(联合雄激素剥夺治疗)的 248 例局部/局部晚期前列腺癌患者进行基因表达分析,采集前列腺癌组织样本,采用聚类分析评估 Metastatic Assay 在预测生化复发无病生存期(BFFS)和无转移生存期(MFS)中的预后价值,比较 Metastatic Assay 阳性与阴性患者的生存差异。

    摘要Background: Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however,>30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate prognostics assays in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. Patients and methods: Independent clinical validation in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. Multivariable Cox proportional hazard regression analysis was used to assess assay performance in predicting biochemical failure-free survival (BFFS) and metastasis free survival (MFS). Results: Gene expression analysis was carried out in 248 patients from the independent validation cohort and the Metastatic Assay applied. Ten-year MFS was 72% for Metastatic Assay positive patients and 94% for Metastatic Assay negative patients [HR 3.21 (1.35–7.67); P=0.003]. On multivariable analysis the Metastatic Assay remained predictive for development of distant metastases [HR 2.71 (1.11–6.63); P=0.030]. The assay retained independent prognostic performance for MFS when assessed with the Cancer of the Prostate Assessment Score (CAPRA) [HR 3.23 (1.22–8.59); P=0.019] whilst CAPRA itself was not significant [HR 1.88, (0.52–6.77); P=0.332]. Conclusions: The Metastatic Assay demonstrated significant prognostic performance in patients treated with radical radiotherapy both alone and independent of standard clinical and pathological variables. The Metastatic Assay could have clinical utility when deciding upon treatment intensification in high-risk patients.

  5. 05 GSE183019 对前列腺癌复发的bulk RNA测序数据进行整合分析,采集了来自不同患者的前列腺组织正常样本和癌症样本,以及外周血样本,采用配对端RNA测序技术进行测序,比较前列腺组织正常与癌症样本的转录组差异。 人源 · 226 例 · GPL24676 · 2021/09/30

    设计对前列腺癌复发的bulk RNA测序数据进行整合分析,采集了来自不同患者的前列腺组织正常样本和癌症样本,以及外周血样本,采用配对端RNA测序技术进行测序,比较前列腺组织正常与癌症样本的转录组差异。

    摘要Prostate cancer is readily curable if detected early. The overall goal of this study is to conduct integrative profiling of tumor and blood genomics and transcriptomics.

  6. 06 GSE70768 研究纳入 259 名前列腺癌患者的 482 个样本,包括 125 个来自根治性前列腺切除术(RP)的肿瘤样本及其 118 个匹配的良性样本,以及 85 个匹配的血液样本。此外,还包括 4 个来自经尿道前列腺切除术(chTURP)的良性样本和 16 个来自去势抵抗性前列腺癌患者的根治性前列腺切除术样本及其 13 个匹配的血液样本。研究采用整合分析方法,结合拷贝数变异(CNA)和阵列转录组学数据,通过表达数量性状位点(eQTL)方法识别影响 mRNA 表达水平的基因组位点,将患者分为五个亚组,并与良性样本进行比较。研究结果在独立验证队列中进一步验证,该队列包含 103 个肿瘤样本及其 99 个匹配的良性样本和 103 个匹配的血液样本。 人源 · 199 例 · GPL10558 · 2015/07/30

    设计研究纳入 259 名前列腺癌患者的 482 个样本,包括 125 个来自根治性前列腺切除术(RP)的肿瘤样本及其 118 个匹配的良性样本,以及 85 个匹配的血液样本。此外,还包括 4 个来自经尿道前列腺切除术(chTURP)的良性样本和 16 个来自去势抵抗性前列腺癌患者的根治性前列腺切除术样本及其 13 个匹配的血液样本。研究采用整合分析方法,结合拷贝数变异(CNA)和阵列转录组学数据,通过表达数量性状位点(eQTL)方法识别影响 mRNA 表达水平的基因组位点,将患者分为五个亚组,并与良性样本进行比较。研究结果在独立验证队列中进一步验证,该队列包含 103 个肿瘤样本及其 99 个匹配的良性样本和 103 个匹配的血液样本。

    摘要Background Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups derived from integrated genomics linked with clinical outcome. Methods In a study of 482 tumour, benign and germline samples from 259 men with primary prostate cancer, we used integrative analysis of copy number alterations (CNA) and array transcriptomics to identify genomic loci that affect expression levels of mRNA in an expression quantitative trait loci (eQTL) approach, to stratify patients into subgroups that we then associated with future clinical behavior, and compared with either CNA or transcriptomics alone. Findings We identified five separate patient subgroups with distinct genomic alterations and expression profiles based on 100 discriminating genes in our separate discovery and validation sets of 125 and 99 men. These subgroups were able to consistently predict biochemical relapse (p=0.0017 and p=0.016 respectively) and were further validated in a third cohort with long-term follow-up (p=0.027). We show the relative contributions of gene expression and copy number data on phenotype, and demonstrate the improved power gained from integrative analyses. We confirm alterations in six genes previously associated with prostate cancer (MAP3K7, MELK, RCBTB2, ELAC2, TPD52, ZBTB4) in prostate cancer, and also identify 94 genes not previously linked to prostate cancer progression that would not have been detected using either transcript or copy number data alone. We confirm a number of previously published molecular changes associated with high risk disease, including MYC amplification, and NKX3-1, RB1 and PTEN deletions, as well as over-expression of PCA3 and AMACR, and loss of MSMB in tumour tissue. A subset of the 100 genes outperforms established clinical predictors of poor prognosis (PSA, Gleason score), as well as previously published gene signatures (p=0•0001). We further show how our molecular profiles can be used for the early detection of aggressive cases in a clinical setting, and inform treatment decisions. Interpretation For the first time this study demonstrates the importance of integrated genomic analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to generation of robust gene sets that are predictive of clinical outcome in independent patient cohorts.

  7. 07 GSE26022 将70例接受根治性前列腺切除术的前列腺癌患者(其中29例发生生化复发,41例未发生生化复发)的福尔马林固定石蜡包埋组织中提取的总RNA用于训练阶段,采用定制的522个前列腺癌相关基因的Prostate DASL和Illumina miRNA微阵列进行表达分析。随后在40例患者中进行独立验证,使用相同平台(13例发生生化复发,27例未发生生化复发)。所有样本均采集自前列腺癌肿瘤组织,临床数据包括PSA、T期和Gleason评分。 人源 · 192 例 · GPL11309 · 2011/06/01

    设计将70例接受根治性前列腺切除术的前列腺癌患者(其中29例发生生化复发,41例未发生生化复发)的福尔马林固定石蜡包埋组织中提取的总RNA用于训练阶段,采用定制的522个前列腺癌相关基因的Prostate DASL和Illumina miRNA微阵列进行表达分析。随后在40例患者中进行独立验证,使用相同平台(13例发生生化复发,27例未发生生化复发)。所有样本均采集自前列腺癌肿瘤组织,临床数据包括PSA、T期和Gleason评分。

    摘要To identify biomarkers predictive of biochemical recurrence, we isolated the RNA from 70 formalin-fixed paraffin-embedded (FFPE) radical prostatectomy specimens with known long term outcome to perform DASL expression profiling with a custom-designed panel of 522 prostate cancer relevant genes that we designed. We identified a panel of ten protein-coding genes and two miRNA genes that could be used to separate patients with and without biochemical recurrence (p < 0.001), as well as for the subset of 42 Gleason score 7 patients (p < 0.001). We performed an independent validation analysis on 40 samples and found that the biomarker panel was also significant at prediction of recurrence for all cases (p = 0.013) and for a subset of 19 Gleason score 7 cases (p = 0.010), both of which were adjusted for relevant clinical information including T-stage, PSA and Gleason score. Importantly, these biomarkers could significantly predict clinical recurrence for Gleason 7 patients. These biomarkers may increase the accuracy of prognostication following radical prostatectomy using formalin-fixed specimens.

  8. 08 GSE220095 对185例前列腺癌(PCa)患者的FFPE活检样本进行转录组基因表达分析,采用RNA-Seq技术检测总RNA,其中179例样本通过质量筛选,3例因未记录生化复发(BCR)时间被排除,最终分析176例患者的转录组数据,75例在随访期间出现BCR。 人源 · 176 例 · GPL16791 · 2023/09/08

    设计对185例前列腺癌(PCa)患者的FFPE活检样本进行转录组基因表达分析,采用RNA-Seq技术检测总RNA,其中179例样本通过质量筛选,3例因未记录生化复发(BCR)时间被排除,最终分析176例患者的转录组数据,75例在随访期间出现BCR。

    摘要Clinical manifestation of PCa is highly variable. Aggressive tumors require radical treatment, while clinically non-significant ones may be suitable for active surveillance. We have previously developed the prognostic ProstaTrend signature mainly on prostatectomy specimens by application of transcriptome‐wide microarray and RNA-sequencing (RNA-Seq) analyses. We used a cohort of 185 tumor specimens obtained from FFPE biopsies for RNA-Seq to facilitate the application of ProstaTrend at the beginning of routine PCa diagnostic. All patients of the FFPE biopsy cohort were treated by radical prostatectomy (RPx) and median follow-up for biochemical recurrence (BCR) was 9 years. Based on the transcriptome data of the FFPE biopsies, we filtered ProstaTrend for genes susceptible to FFPE-associated degradation via regression analysis. ProstaTrend was additionally restricted to genes with concordant prognostic effects in the RNA-Seq TCGA prostate adenocarcinoma (PRAD) cohort to ensure robust and broad applicability. The prognostic relevance of the refined Transcriptomic Risk Score (TRS) was analyzed by Kaplan-Meier curves, Cox-regression models in our FFPE-biopsy cohort and 9 other public datasets from PCa patients with BCR as primary endpoint. The TRS based on the revised ProstaTrend signature, which included 204 genes, was significantly associated with BCR in the FFPE biopsy cohort (Cox-regression p-value <0.001). The TRS retained prognostic relevance when adjusted for Gleason Score (GS). We confirmed a significant association with BCR in 9 independent cohorts with a total of 1109 PCa patients. Comparison of the prognostic performance of the TRS with 17 other prognostically relevant PCa panels revealed that the revised ProstaTrend was among the best-ranked panels.

  9. 09 GSE54460 对100名患者的106个FFPE前列腺切除样本进行RNA测序,所有样本均来自不同机构,包括Atlanta VA Medical Center、U. Toronto Sunnybrook Research Centre和Moffitt Cancer Center。研究通过RNA提取和cDNA文库构建,采用RNA-Seq策略,使用GPL11154平台进行测序,检测总RNA并分析基因表达差异,识别前列腺癌复发的生物标志物。 人源 · 106 例 · GPL11154 · 2014/04/11

    设计对100名患者的106个FFPE前列腺切除样本进行RNA测序,所有样本均来自不同机构,包括Atlanta VA Medical Center、U. Toronto Sunnybrook Research Centre和Moffitt Cancer Center。研究通过RNA提取和cDNA文库构建,采用RNA-Seq策略,使用GPL11154平台进行测序,检测总RNA并分析基因表达差异,识别前列腺癌复发的生物标志物。

    摘要In an effort to identify biomarkers of recurrence, we have performed global RNA-sequencing on 106 formalin-fixed, paraffin-embedded (FFPE) prostatectomy samples from 100 patients at three independent sites, and identified a new set of biomarkers of biochemical recurrence composed of a 24-gene panel. We validated this 24-gene panel on an independent publicly available dataset of 140 patients and this new panel outperformed previously published markers based on cell proliferation gene sets in terms of prediction of biochemical recurrence (BCR). In addition we identified differences in gene expression between Gleason Pattern 4+3 and Gleason Pattern 3+4 tumors.

  10. 10 GSE317455 对前列腺癌复发的bulk RNA进行转录分析,采集组织样本并提取总RNA,采用NanoString免疫分析面板检测730个免疫相关基因,比较不同分组间的基因表达差异。 人源 · 102 例 · GPL32232;33084 · 2026/01/31

    设计对前列腺癌复发的bulk RNA进行转录分析,采集组织样本并提取总RNA,采用NanoString免疫分析面板检测730个免疫相关基因,比较不同分组间的基因表达差异。

    摘要This SuperSeries is composed of the SubSeries listed below.

  11. 11 GSE26242 从70例已知长期预后结果的前列腺癌根治术标本中提取RNA,使用定制的522个前列腺癌相关基因DASL表达谱进行训练分析,其中29例发生生化复发,41例未发生。随后在40例患者样本中独立验证,采用相同平台检测,13例发生生化复发,27例未发生。检测包括DASL表达谱和Illumina miRNA微阵列,主要比较生化复发组与未发生组的基因表达差异,并调整PSA、T期和Gleason评分等临床信息。 人源 · 96 例 · GPL11309 · 2011/06/01

    设计从70例已知长期预后结果的前列腺癌根治术标本中提取RNA,使用定制的522个前列腺癌相关基因DASL表达谱进行训练分析,其中29例发生生化复发,41例未发生。随后在40例患者样本中独立验证,采用相同平台检测,13例发生生化复发,27例未发生。检测包括DASL表达谱和Illumina miRNA微阵列,主要比较生化复发组与未发生组的基因表达差异,并调整PSA、T期和Gleason评分等临床信息。

    摘要To identify biomarkers predictive of biochemical recurrence, we isolated the RNA from 70 formalin-fixed paraffin-embedded (FFPE) radical prostatectomy specimens with known long term outcome to perform DASL expression profiling with a custom-designed panel of 522 prostate cancer relevant genes that we designed. We identified a panel of ten protein-coding genes and two miRNA genes that could be used to separate patients with and without biochemical recurrence (p < 0.001), as well as for the subset of 42 Gleason score 7 patients (p < 0.001). We performed an independent validation analysis on 40 samples and found that the biomarker panel was also significant at prediction of recurrence for all cases (p = 0.013) and for a subset of 19 Gleason score 7 cases (p = 0.010), both of which were adjusted for relevant clinical information including T-stage, PSA and Gleason score. Importantly, these biomarkers could significantly predict clinical recurrence for Gleason 7 patients. These biomarkers may increase the accuracy of prognostication following radical prostatectomy using formalin-fixed specimens.

  12. 12 GSE216490 对78例Hispanic/Latino前列腺癌患者进行RNA-测序,根据非肿瘤样本中ERG表达的中位数1.5倍变化将肿瘤分为ERGhigh和ERGlow组,识别出差异表达基因(DEGs)并进行代谢通路富集分析,评估其与生化复发(BCR)的关联。 人源 · 95 例 · GPL10999;18573 · 2022/10/27

    设计对78例Hispanic/Latino前列腺癌患者进行RNA-测序,根据非肿瘤样本中ERG表达的中位数1.5倍变化将肿瘤分为ERGhigh和ERGlow组,识别出差异表达基因(DEGs)并进行代谢通路富集分析,评估其与生化复发(BCR)的关联。

    摘要Background The role of ERG-status molecular subtyping in prognosis of prostate cancer (PCa) is still under debate. In this study, we identified differentially expressed genes (DEGs) according to ERG-status to explore their enriched pathways and implications in prognosis in Hispanic/Latino PCa patients. Methods RNA from 78 Hispanic PCa tissues from radical prostatectomies (RP) were used for RNA-sequencing. ERGhigh/ERGlow tumor groups were determined based on the 1.5-fold change median expression in non-tumor samples. DEGs with a False Discovery Rate (FDR) < 0.01 and a fold change > 2 were identified between ERGhigh and ERGlow tumors and submitted to enrichment analysis in MetaCore. Survival and association analyses were performed to evaluate biochemical recurrence (BCR)-free survival. Results The identification of 150 DEGs between ERGhigh and ERGlow tumors revealed clustering of most of the non-BCR cases (60%) into de ERGhigh group and most of the BCR cases (60.8%) in ERGlow group. Kaplan-Meier survival curves showed a worst BCR-free survival for ERGlow patients, and a significant reduced risk of BCR was observed for ERGhigh cases (OR = 0.29 (95%CI, 0.10-0.8). Enrichment pathway analysis identified metabolic-related pathways, such as the renin-angiotensin system and angiotensin maturation system, the linoleic acid metabolism, and polyamines metabolism in these ERG groups. Conclusions ERGlow tumor cases were associated with poor BCR-free survival in our Hispanic/Latino patients, with metabolism-related pathways altered in the BCR progression. Impact Our findings suggest the need to dissect the role of diet, metabolism and lifestyle as risk factors for more aggressive PCa subtypes.

  13. 13 GSE70769 本研究使用来自 259 名前列腺癌患者的 482 个样本,包括肿瘤组织、良性组织和血液样本,通过整合拷贝数变异(CNA)和基因表达数据,识别影响 mRNA 表达水平的基因组位点,并将患者分为五个亚组,比较各亚组与良性组织的差异,以预测生化复发风险。 人源 · 94 例 · GPL10558 · 2015/07/30

    设计本研究使用来自 259 名前列腺癌患者的 482 个样本,包括肿瘤组织、良性组织和血液样本,通过整合拷贝数变异(CNA)和基因表达数据,识别影响 mRNA 表达水平的基因组位点,并将患者分为五个亚组,比较各亚组与良性组织的差异,以预测生化复发风险。

    摘要Background Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups derived from integrated genomics linked with clinical outcome. Methods In a study of 482 tumour, benign and germline samples from 259 men with primary prostate cancer, we used integrative analysis of copy number alterations (CNA) and array transcriptomics to identify genomic loci that affect expression levels of mRNA in an expression quantitative trait loci (eQTL) approach, to stratify patients into subgroups that we then associated with future clinical behavior, and compared with either CNA or transcriptomics alone. Findings We identified five separate patient subgroups with distinct genomic alterations and expression profiles based on 100 discriminating genes in our separate discovery and validation sets of 125 and 99 men. These subgroups were able to consistently predict biochemical relapse (p=0.0017 and p=0.016 respectively) and were further validated in a third cohort with long-term follow-up (p=0.027). We show the relative contributions of gene expression and copy number data on phenotype, and demonstrate the improved power gained from integrative analyses. We confirm alterations in six genes previously associated with prostate cancer (MAP3K7, MELK, RCBTB2, ELAC2, TPD52, ZBTB4) in prostate cancer, and also identify 94 genes not previously linked to prostate cancer progression that would not have been detected using either transcript or copy number data alone. We confirm a number of previously published molecular changes associated with high risk disease, including MYC amplification, and NKX3-1, RB1 and PTEN deletions, as well as over-expression of PCA3 and AMACR, and loss of MSMB in tumour tissue. A subset of the 100 genes outperforms established clinical predictors of poor prognosis (PSA, Gleason score), as well as previously published gene signatures (p=0•0001). We further show how our molecular profiles can be used for the early detection of aggressive cases in a clinical setting, and inform treatment decisions. Interpretation For the first time this study demonstrates the importance of integrated genomic analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to generation of robust gene sets that are predictive of clinical outcome in independent patient cohorts.

  14. 14 GSE51066 针对根治性前列腺切除术后生化复发的前列腺癌患者,收集其福尔马林固定石蜡包埋组织样本,根据是否发生转移分为两组,采用基因组分类器评分与传统临床病理指标进行比较,以预测转移性疾病进展。 人源 · 85 例 · GPL5188 · 2016/09/19

    设计针对根治性前列腺切除术后生化复发的前列腺癌患者,收集其福尔马林固定石蜡包埋组织样本,根据是否发生转移分为两组,采用基因组分类器评分与传统临床病理指标进行比较,以预测转移性疾病进展。

    摘要BACKGROUND: Due to their varied outcomes, men with biochemical recurrence (BCR) following radical prostatectomy (RP) present a management dilemma. Here, we evaluate Decipher, a genomic classifier (GC), for its ability to predict metastasis following BCR. METHODS: The study population included 85 clinically high-risk patients who developed BCR after RP. Time-dependent receiver operating characteristic (ROC) curves, weighted Cox proportional hazard models, and decision curves were used to compare GC scores to Gleason score (GS), PSA doubling time (PSAdT), time to BCR (ttBCR), the Stephenson nomogram, and CAPRA-S for predicting metastatic disease progression. All tests were two-sided with a type I error probability of 5%. RESULTS: GC scores stratified men with BCR into those who would or would not develop metastasis (8% of patients with low versus 40% with high scores developed metastasis, p<0.001). The area under the curve for predicting metastasis after BCR was 0.82 (95% CI, 0.76-0.86) for GC, compared to GS 0.64 (0.58-0.70), PSAdT 0.69 (0.61-0.77) and ttBCR 0.52 (0.46-0.59). Decision curve analysis showed that GC scores had a higher overall net benefit compared to models based solely on clinicopathologic features. In multivariable modeling with clinicopathologic variables, GC score was the only significant predictor of metastasis (p=0.003). CONCLUSIONS: When compared to clinicopathologic variables, GC better predicted metastatic progression among this cohort of men with BCR following RP. While confirmatory studies are needed, these results suggest that use of GC may allow for better selection of men requiring earlier initiation of treatment at the time of BCR.

  15. 15 GSE316750 对41名接受根治性前列腺切除术的前列腺癌患者,采集其恶性与相邻良性前列腺组织样本进行RNA-seq,比较同一患者内恶性与良性组织的转录组差异,并分析差异基因在生化复发(BCR)有无患者中的表达情况。 人源 · 82 例 · GPL21290 · 2026/05/26

    设计对41名接受根治性前列腺切除术的前列腺癌患者,采集其恶性与相邻良性前列腺组织样本进行RNA-seq,比较同一患者内恶性与良性组织的转录组差异,并分析差异基因在生化复发(BCR)有无患者中的表达情况。

    摘要More accurate methods for early prediction of cancer aggressiveness are essential for enhanced prostate cancer (PC) treatment. In this study, the transcriptome profiles from malignant and adjacent benign prostate tissue samples were compared in 41 patients who underwent radical prostatectomy. Hierarchical clustering clearly separated benign and malignant tissues and included expected transcriptional changes associated with carcinogenesis. Using reproducibility-optimized statistical testing (ROTS), we identified 45 genes whose expression differed between paired malignant and benign prostate tissue from the same patient (FDR < 0.05) in patients with and without biochemical recurrence (BCR). Within this individualized approach, two interconnected regulatory pathways underlying the pathogenesis were identified: one centered on FOS, NR4A, and EGR family transcription factors, with strong involvement of TNFα signaling, and another, a less dense network, centered on IL6. Expression of the 45 identified transcripts was also higher in the more aggressive Luminal B-type PC than in Luminal A- and Basal-type PC, further underscoring their association with PC aggressiveness. A machine learning method (SIVS) was then used to further define five transcripts, BPIFB2, C11orf96, DUSP5, NR4A2, and NR4A3, whose individualized malignant to benign expression differences were most strongly associated with an increased risk of BCR, and thus, providing novel information on their potential involvement in processes increasing the PC aggressiveness.

  16. 16 GSE25136 对79例已知复发状态的前列腺癌患者进行基因表达分析,比较复发组与非复发组的差异,以开发更准确的预后标志物。 人源 · 79 例 · GPL96 · 2010/11/05

    设计对79例已知复发状态的前列腺癌患者进行基因表达分析,比较复发组与非复发组的差异,以开发更准确的预后标志物。

    摘要The derivation of molecular signatures indicative of disease status and predictive of subsequent behavior could facilitate the optimal choice of treatment for prostate cancer patients. In this study, we conducted a computational analysis of gene expression profile data obtained from 79 cases, 39 of which were classified as having disease recurrence, to investigate whether advanced computational algorithms can derive more accurate prognostic signatures for prostate cancer. At the 90% sensitivity level, a newly derived prognostic genetic signature achieved 85% specificity. This is the first reported genetic signature to outperform a clinically used postoperative nomogram. Furthermore, a hybrid prognostic signature derived by combination of the nomogram and gene expression data significantly outperformed both genetic and clinical signatures, and achieved a specificity of 95%. Our study demonstrates the feasibility of utilizing gene expression information for highly accurate prostate cancer prognosis beyond the current clinical systems, and shows that more advanced computational modeling of tissue-derived microarray data is warranted before clinical application of molecular signatures is considered.

  17. 17 GSE317416 对局部早期前列腺癌患者进行多组学分析,包括靶向测序、转录和蛋白空间分析,比较具有生化复发(BRC)与无生化复发的肿瘤样本,检测与生化复发及临床风险相关的基因表达特征。 人源 · 51 例 · GPL32232 · 2026/01/31

    设计对局部早期前列腺癌患者进行多组学分析,包括靶向测序、转录和蛋白空间分析,比较具有生化复发(BRC)与无生化复发的肿瘤样本,检测与生化复发及临床风险相关的基因表达特征。

    摘要The management of intermediate-risk early prostate cancer (PCa) is challenging due to the difficulty in distinguishing indolent from aggressive tumors. This study explores the impact of genomic alterations on the tumor and its microenvironment (TME). We performed multi-omic profiling in a cohort of 53 localized PCa using targeted sequencing, transcriptional and proteomic spatial profiling. Somatic mutations and copy number alterations in RB1 (21%), PTEN (18%), and TP53 (9%) were identified. Kaplan-Meier analysis revealed that alterations in the RB and Cell Cycle pathways, particularly aberrations in PTEN, TP53, or RB1, were associated with shorter biochemical recurrence-free survival (p < 0.001). Spatial proteomic analysis demonstrated a complex immune landscape in patients with mutations. The tumor compartment demonstrated higher expression of immune checkpoint markers, T-cell activation proteins, and proliferation markers; and a TME that is enriched with CD8+ T cells and antigen-presenting cells, but also with immunosuppressive M2 macrophages, suggesting adaptive immune resistance. Our analysis demonstrates that genomic alterations in PTEN, TP53, or RB1 are not only prognostic for poor outcomes but also actively shape a unique, immunologically active yet suppressed TME.

  18. 18 GSE46602 对36名前列腺癌患者的肿瘤组织和14名正常前列腺活检样本进行基因表达分析,通过无监督层次聚类将肿瘤样本分为两组,其中一组显著过代表生化复发病例,比较两组间的基因表达差异。样本来源为激光显微切割的肿瘤组织和良性前列腺腺体,检测使用微阵列技术(GPL570)。 人源 · 50 例 · GPL570 · 2015/07/01

    设计对36名前列腺癌患者的肿瘤组织和14名正常前列腺活检样本进行基因表达分析,通过无监督层次聚类将肿瘤样本分为两组,其中一组显著过代表生化复发病例,比较两组间的基因表达差异。样本来源为激光显微切割的肿瘤组织和良性前列腺腺体,检测使用微阵列技术(GPL570)。

    摘要Prostate cancer is a leading cause of cancer death amongst males. The main clinical dilemma in treating prostate cancer is the high number of indolent cases that confer a significant risk of over diagnosis and over treatment. In this study we have performed a genome expression profiling of tumor tissue specimens from 36 patients with prostate cancer to identify transcripts that delineate aggressive and indolent cancer. We included normal prostate biopsies from 14 patients in our analysis. Unsupervised hierarchical cluster analysis separated the cancer samples into two groups with a significant overrepresentation of tumors from patients with biochemical recurrence in one of the groups (Chi2, p=0.02). The samples were separated by basically three clusters of genes that showed differential expression between the two sample clusters - totaling 371 transcripts. Ingenuity Pathway Analysis revealed that one cluster contained genes associated with invasive properties of the tumor, another genes associated with the cell cycle, and the last cluster genes involved in several biological functions. We successfully validated the transcripts association with recurrence using two publicly available patient datasets totaling 669 patients. Twelve genes were found to be independent predictors of recurrence in multivariate logistical regression analysis.

  19. 19 GSE111177 对前列腺癌复发患者的术前活检和术后去势治疗标本进行全转录组分析,识别出对ADT反应差异的两个患者亚组(高影响组和低影响组),发现所有患者均失去AR依赖性亚型(PCS2)的转录特征,高影响组保留更具侵略性的亚型(PCS1)信号,而低影响组更接近AR抑制亚型(PCS3)特征,通过计算分析确定高影响组网络中富集的转录因子协调组(TFCGs),并与转移性病变中的33个共同TFCGs进行比较,包括SOX4/FOXA2/GATA4、ERF/ETV5/ETV3/ELF4以及包含JUN、JUNB、JUND、FOS、FOSB和FOSL1的TFCG。 人源 · 48 例 · GPL16791 · 2018/10/11

    设计对前列腺癌复发患者的术前活检和术后去势治疗标本进行全转录组分析,识别出对ADT反应差异的两个患者亚组(高影响组和低影响组),发现所有患者均失去AR依赖性亚型(PCS2)的转录特征,高影响组保留更具侵略性的亚型(PCS1)信号,而低影响组更接近AR抑制亚型(PCS3)特征,通过计算分析确定高影响组网络中富集的转录因子协调组(TFCGs),并与转移性病变中的33个共同TFCGs进行比较,包括SOX4/FOXA2/GATA4、ERF/ETV5/ETV3/ELF4以及包含JUN、JUNB、JUND、FOS、FOSB和FOSL1的TFCG。

    摘要Background: Patients with locally advanced or recurrent prostate cancer typically undergo androgen deprivation therapy (ADT), but the benefits are often short-lived, and responses are variable. ADT failure results in castration-resistant prostate cancer (CRPC), that inevitably leads to metastasis. We hypothesized that differences in tumor transcriptional programs may reflect differential responses to ADT and subsequent metastasis. Results: We performed whole transcriptome analysis of 20 patient-matched Pre-ADT biopsies and 20 Post-ADT prostatectomy specimens, and identified two subgroups of patients (high impact and low impact groups) that exhibited distinct transcriptional changes in response to ADT. We found that all patients lost AR-dependent subtype (PCS2) transcriptional signatures. The high impact group maintained the more aggressive subtype (PCS1) signal, while the low impact group more resembled an AR-suppressed (PCS3) subtype. Computational analyses identified transcription factor coordinated groups (TFCGs) enriched in the high impact group network. Leveraging a large public dataset of over 800 metastatic and primary samples, we identified 33 TFCGs in common between high impact group and metastatic lesions, including SOX4/FOXA2/GATA4, ERF/ETV5/ETV3/ELF4, and a TFCG containing JUN, JUNB, JUND, FOS, FOSB, and FOSL1. The majority of metastatic TFCGs were subsets of larger TFCGs in the high impact group network, suggesting refinement of critical TFCGs in prostate cancer progression. Conclusions: We have identified TFCGs associated with pronounced initial transcriptional response to ADT, aggressive signatures, and metastasis. Our findings suggest multiple new hypotheses that could lead to novel combination therapies to prevent development of CRPC following ADT.

  20. 20 GSE41408 分析根治性前列腺切除术后的前列腺癌样本的基因表达,样本含有超过70%癌组织和少于30%间质组织,每个样本进行一次微阵列检测。 人源 · 48 例 · GPL5175 · 2013/02/11

    设计分析根治性前列腺切除术后的前列腺癌样本的基因表达,样本含有超过70%癌组织和少于30%间质组织,每个样本进行一次微阵列检测。

    摘要ERG overexpression is the most frequent molecular alteration in prostate cancer. We analyzed different stages of prostate cancer to identify genes that were coexpressed with ERG overexpression. In primary prostate tumors, it was shown that TDRD1 expression was the strongest correlated gene with ERG overexpression and we suggest TDRD1 as a direct ERG target gene.

  21. 21 GSE28403 对11例去势抵抗性前列腺癌和7例晚期前列腺癌样本进行阵列-CGH和基因表达微阵列分析,整合DNA和RNA数据以识别由基因扩增驱动的过表达基因。在前列腺癌细胞中通过RNA干扰沉默这些基因,并在非癌性前列腺上皮细胞中过表达FAM110B,分析其对细胞生长、染色体不稳定性及抗原呈递的影响。 人源 · 47 例 · GPL570;2879;2873;7182 · 2011/08/29

    设计对11例去势抵抗性前列腺癌和7例晚期前列腺癌样本进行阵列-CGH和基因表达微阵列分析,整合DNA和RNA数据以识别由基因扩增驱动的过表达基因。在前列腺癌细胞中通过RNA干扰沉默这些基因,并在非癌性前列腺上皮细胞中过表达FAM110B,分析其对细胞生长、染色体不稳定性及抗原呈递的影响。

    摘要Background: Castration-resistant prostate cancer (CRPC) represents a therapeutic challenge for current medications. Methods: In order to explore the molecular mechanisms involved in CRPC progression and to identify new therapeutic targets, we analyzed a unique sample set of 11 castration-resistant prostate cancers and 7 advanced tumors by array-CGH and gene expression microarrays. The genome-wide DNA and RNA data were integrated to identify genes whose overexpression was driven by their amplification. To assess the functional role of these genes, their expression was analyzed in a transcriptional dataset of 329 clinical prostate cancers and the corresponding gene products were silenced using RNA interference in prostate cancer cells. Results: Six recurrent genetic targets were identified in the CRPCs; ATP1B1, AR, FAM110B, LAS1L, MYC and YIPF6. In addition to AR and MYC, FAM110B emerged as a potential key gene involved in CRPC progression in a subset of the tumors. FAM110B was able to regulate AR signaling in prostate cancer cells and FAM110B itself was regulated by androgens. FAM110B siRNA inhibited the growth of prostate cancer cells in vitro, and this effect was substantially enhanced in androgen deficient conditions. Ectopic FAM110B expression in non-cancerous epithelial prostate cells induced aneuploidy and impaired antigen presentation. Conclusions: The DNA / RNA gene outlier detection combined with siRNA cell proliferation assay identified FAM110B as a potential growth promoting key gene for CRPC. FAM110B appears to have a key role in the androgen signaling and progression of CRPC impacting multiple cancer hallmarks and therefore highlighting a potential therapeutic target.

  22. 22 GSE18916 对42例前列腺癌样本(16例生化复发与26例无复发)进行基因表达分析,样本均来自接受根治性前列腺切除术的患者,收集时间在1998年至2001年之间。研究采用微阵列技术检测总RNA的表达谱,通过Cy3和Cy5标记的cRNA重复杂交获取强度值,使用几何均值作为样本强度值,并通过量化归一化和贝叶斯方法调整批次效应。 人源 · 42 例 · GPL4051 · 2011/06/15

    设计对42例前列腺癌样本(16例生化复发与26例无复发)进行基因表达分析,样本均来自接受根治性前列腺切除术的患者,收集时间在1998年至2001年之间。研究采用微阵列技术检测总RNA的表达谱,通过Cy3和Cy5标记的cRNA重复杂交获取强度值,使用几何均值作为样本强度值,并通过量化归一化和贝叶斯方法调整批次效应。

    摘要We analyzed the protein-coding and non-coding gene expression profiles of 64 samples of prostate cancer primary tumors. All samples were collected between 1998 and 2001 with informed consent from patients subjected to radical prostatectomy at Hospital Sirio-Libanes in São Paulo. Selected patients were identified with clinical Stage T1-2 prostate cancer and no lymph node involvement, and received no adjuvant treatment after surgery as long as they remained recurrence-free. Biochemical recurrence was defined as an increase in patient blood PSA level to 0.2 ng per mL of blood at any time during the 5-year follow-up after prostatectomy. For this kind of experiment, also called self-self hybridization, the microarrays were cohybridized with each of Cy3- and Cy5-labeled cRNA replicates. This strategy has been used to derive intensity-dependent cutoffs to classify a gene as differentially expressed or divergent in comparative genomic hybridization (CGH) studies. The comparative analysis of constant fold change cutoffs and intensity-dependent ones has been extensively discussed, showing a superior performance of the intensity-dependent strategy.

  23. 23 GSE278135 对前列腺癌患者(n=18)的FFPE组织进行RNA-Seq和DNA甲基化分析,根据生化复发状态分为有和无两组,比较其转录组和甲基组特征。其中6个样本因平均检测p值>0.05未参与甲基组分析,且包含技术重复以评估数据可重复性。 人源 · 18 例 · GPL24676 · 2025/03/23

    设计对前列腺癌患者(n=18)的FFPE组织进行RNA-Seq和DNA甲基化分析,根据生化复发状态分为有和无两组,比较其转录组和甲基组特征。其中6个样本因平均检测p值>0.05未参与甲基组分析,且包含技术重复以评估数据可重复性。

    摘要Prostate cancer (PCa) is a major health burden world-wide and despite early treatment, a very large proportion of patients present with biochemical recurrence (BCR) post-treatment, reflected by a rise in PSA over a clinical threshold. Novel transcriptomic and epigenomic biomarkers can provide a powerful tool for clinical management of PCa. Here we provide matched RNA-Sequencing and array-based genome-wide DNA methylome data of PCa patients (n = 17) with, or without, evidence of BCR following early radical prostatectomy. We have utilized Formalin-Fixed Paraffin-Embedded tissues to generate this data and included technical replicates to provide further validity of the data. We describe the sample features, experimental design, methods and bioinformatic pipeline for processing these multi-omic data. Importantly, we provide comprehensive clinical, histopathological, and follow-up data for each patient to enable correlating transcriptome and methylome features with clinical features. Our data will contribute towards the efforts of developing epigenomic and transcriptomic markers for BCR and also facilitate a deeper understanding of the molecular basis of PCa recurrence.

微信二维码

课题合作 · 扫码加微信

bioinformaticsboy